Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Ocugen, Inc.NASDAQ: OCGN
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 12.3% from a year ago
Total current assets stood at $38.55M at the end of Q1 FY2026, down 12.3% from a year earlier and up 58.4% from the prior quarter. Over 3 fiscal years it compounded at -37.2% a year.
Context
- Total current assets amounted to 67.7% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -12.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 24.34M USD
- Year-over-year change
- -60.5%
- 4-year CAGR
- -30.2%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.34M | -60.5% |
| FY2024 | 2024-12-31 | 61.68M | +43.5% |
| FY2023 | 2023-12-31 | 42.97M | -56.4% |
| FY2022 | 2022-12-31 | 98.49M | -4.0% |
| FY2021 | 2021-12-31 | 102.65M | — |
Total Current Assets vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's Mar 2026 total current assets of $38.55M is the lowest of the 10 companies compared; the peer median is $195.69M.
- Its year-over-year change of -12.3% is the 7th highest of 10, against a peer median of +7.3%.
- Total current assets amounts to 67.7% of total assets for OCGN, versus a peer median of 93.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $514.08M | -0.7% | +45.9% | 91.7% |
| Mar 2026 | $338.67M | +45.6% | +19.9% | 97.7% | |
| Mar 2026 | $276.77M | +7.3% | -11.0% | 94.9% | |
| Mar 2026 | $246.75M | -16.8% | +47.5% | 93.8% | |
| Mar 2026 | $195.69M | +57.6% | +2.5% | 95.4% | |
| Mar 2026 | $186.03M | -24.3% | -10.2% | 69.2% | |
| Mar 2026 | $180.36M | +87.5% | -21.3% | 63.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M | -39.8% | -21.1% | 99.7% |
| Mar 2026 | $56.16M | +12.4% | -0.5% | 51.3% | |
| Mar 2026 | $38.55M | -12.3% | -37.2% | 67.7% | |
| Peer median (excluding OCGN) | $195.69M | +7.3% | -0.5% | 93.8% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 94.96M | 77.56M | 39.46M | 58.51M | 18.57M |
| Short-term Investments | 0 | 13.37M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.56M | 3.51M | 3.17M | 5.77M |
| Total Current Assets | 102.65M | 98.49M | 42.97M | 61.68M | 24.34M |
| Property, Plant & Equipment (Net) | 1.16M | 6.05M | 17.29M | 16.55M | 14.39M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.95M | 4.09M | 4.29M | 4.21M | 4.78M |
| Total Non-current Assets | 3.12M | 10.14M | 21.58M | 20.76M | 19.18M |
| Total Assets | 105.76M | 108.63M | 64.55M | 82.44M | 43.52M |
| Account Payables | 2.31M | 8.06M | 3.17M | 4.24M | 6.2M |
| Short-term Debt | 0 | 0 | 0 | 1.33M | 1.25M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 11.22M | 10.53M | 8.37M | 5.91M |
| Other Current Liabilities | 1.72M | 3.11M | 1.03M | 5.26M | 6.69M |
| Total Current Liabilities | 7M | 28.53M | 17.09M | 21.59M | 23.04M |
| Long-term Debt | 1.71M | 2.29M | 2.8M | 27.35M | 27.54M |
| Deferred Tax Liabilities | 0 | 0 | 918K | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | (918K) | 0 | 0 |
| Other Non-current Liabilities | 0 | 244K | 527K | 564K | 1.6M |
| Total Non-current Liabilities | 2.94M | 6.12M | 6.89M | 31.22M | 32.64M |
| Total Liabilities | 9.94M | 34.65M | 23.98M | 52.81M | 55.68M |
| Common Stock | 2M | 2.22M | 2.57M | 2.92M | 3.13M |
| Retained Earnings | (131.67M) | (223.09M) | (286.17M) | (340.22M) | (408.07M) |
| Accumulated OCI | (0) | 26K | 20K | 48K | 61K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.82M | 73.98M | 40.56M | 29.63M | (12.17M) |
| Total Debt | 3.31M | 6.37M | 6.94M | 32.5M | 33.14M |
| Net Debt | (91.65M) | (71.19M) | (32.52M) | (26.01M) | 14.57M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.